The FDA has provided a date of April 18, 2025, to review the application for Dupixent to treat patients with chronic ...

Regeneron and Sanofi's Dupixent sBLA for treating chronic spontaneous urticaria in patients 12+ gets FDA review, with a ...

Regeneron (REGN) and Sanofi (SNY) announced that the FDA has accepted for review the resubmission of the supplemental Biologics License ...

Dupixent sBLA accepted for FDA review for the treatment of chronic spontaneous urticaria Resubmission includes new pivotal data which confirm ...

The US Food and Drug Administration (FDA) has accepted for review the resubmission of the supplemental biologics license application (sBLA) for Dupixent (dupilumab) to treat adults and pediatric ...

The FDA last year turned away the companies' application and asked for additional efficacy data. Regeneron and Sanofi said the resubmission adds results from an additional Phase 3 study of Dupixent in ...

The BOREAS Phase III trial showed DUPIXENT reduced exacerbations by 30% and improved lung function by 160 mL at 52 weeks.

Eli Lilly’s Ebglyss (lebrikizumab-lbkz) showed improvement in skin clearance and itch relief for most patients with ...

Patients had been previously treated with Dupixent with little success. However, the results of this latest Ebglyss study ...

2 Top Growth Stocks to Buy on the Dip was originally published by The Motley Fool ...

Apogee Therapeutics' APG777 shows promise in treating atopic dermatitis with less frequent dosing. See why I rate APGE stock ...

Citigroupa expanded its biotech coverage on Wednesday, adding five more stocks to the roster including Amgen (NASDAQ:AMGN), Biogen (NASDAQ:BIIB), Gilead (NASDAQ:GILD), Regeneron (NASDAQ:REGN), and ...